Clinical Validation of a Neointima-Inducing Inflow Cannula in a Continuous Flow Left Ventricular Assist Device. Issue 3 (1st December 2022)

• Record Type: Journal Article
• Authors: Yamada, Yukiko; Kikuchi, Noriko; Yoshizawa, Saeko; Ichihara, Yuki; Hattori, Hidetoshi; Saito, Satoshi; Nunoda, Shinichi; Niinami, Hiroshi
• Is Part Of: ASAIO journal. Volume 69:Issue 3(2023)
• Page Start: 299
• Page End: 303
• Publication Date: 2022-12-01
• Subjects: wedge thrombus -- inflow cannula -- left ventricular assist device -- neointima -- thromboembolism; Artificial organs -- Periodicals; 617
• DOI: 10.1097/MAT.0000000000001865
• Languages: English
• ISSNs: 1058-2916

Abstract

Abstract : Wedge thrombus formation around the inflow cannula of a continuous left ventricular assist device (LVAD) is a source of systemic thromboemboli. We previously reported the potential advantages of a new inflow cannula wrapped with titanium mesh (GU30) over the standard smooth surface oblique cut cannula (GU10). The objective of the present study was to clinically validate this new cannula. A retrospective cohort analysis of patients with implanted LVAD (EVAHEART) comparing the GU10 to the GU30 was conducted. Clinical outcomes, including survival, the incidence of thromboembolism, and bleeding events, were compared. Gross and histopathological analyses of explanted GU30 cannula were conducted following transplant or patient death. No significant differences in the survival rate, severe emboli, or cerebral bleeding were observed during the LVAD implantation. However, severe emboli occurred earlier after LVAD implantation when using the GU30 cannula compared with the GU10. In cases of long LVAD support, the neointima fully covered the inflow of the GU30 cannulae without wedge thrombus formation. The titanium mesh-wrapped inflow cannulae did not reduce the overall incidence of neurological events significantly. However, the titanium mesh-wrapped inflow cannula induced autologous neointimal growth over the cannula and prevented wedge thrombus formation in late-phase LVAD implantation.